
Semaglutide 2.4 mg Reduces 10-year Risk of Type 2 Diabetes in Patients with Overweight, Obesity

ADA 2022: Reduction in risk of progression to type 2 diabetes of 60% was seen in STEP program clinical trial participants with overweight or obesity.
In patients with overweight or obesity, once-weekly semaglutide 2.4 mg reduced the 10-year risk of developing type 2 diabetes (T2D) by approximately 60%, according to new findings presented at the 82nd
The risk reduction was consistent regardless of initial glycemic status, according to the study abstract, and sustained treatment required to maintain the benefit, according to the authors.
Semaglutide, a sodium-glucose contransporter-2 (SGLT-2) inhibitor, combined with diet and exercise, was assessed for chronic weight management against placebo in the phase 3 STEP clinical trial program which was the foundation for the US Food and Drug Administration
The current analysis, led by W Timothy Garvey, MD, Butterworth professor of medicine in the department of nutrition science at the University of Alabama School of Medicine, is based on data from 2 phase 3 STEP program trials: the
The post hoc calcuation of 10-year risk of developing T2D was performed using Cardiometabolic Disease Staging (CMDS), a validated Bayesian logistic regression of T2D risk factors, including age, sex, race BMI, triglycerides, HDL, blood pressure and fasting plasma glucose.
When they analyzed the data, Garvey and colleagues found a decrease in risk scores at 68 weeks in both groups: from 18% to 7% with semaglutide and from 18% to 16% with placebo, a reduction of 61% vs 13% (p<.01). For participants receiving semaglutide 2.4 mg, the majority of reduction in risk score occurred during the first 20 weeks, dropping from 21% to 11%, they observed. With continued use of semaglutide from weeks 20 to 68, risk scores fell to 8%, the team reported, but increased to 15% after the switch from the study drug to placebo, a reduction of risk of 32% vs an increase of 41% (p<.01).
The investigators further found that baseline risk scores (week 0) were higher among patients with prediabetes than those with normoglycemia, yet treatment effects were comparable between groups at week 68 (pinteraction =.45).
According to the authors, the observed changes in the proxy risk for developing T2D mirrored changes in body weight, ie, a reduction of 17% with semaglutide vs 3% achieved with placebo in the STEP 1 trial and a reduction of 11% for weeks 0 to 20 with semaglutide in STEP 4. In STEP 4, continued treatment with semaglutide led to an additional reduction in weight of 9% which turned to a regain of 6% with the switch to placebo for weeks 20 to 68.
“In summary, treatment with semaglutide reduces the 10-year risk of type 2 diabetes by approximately 60% regardless of initial glycemic status, with sustained treatment required to maintain this benefit,” they concluded. “These data suggest semaglutide could help prevent type 2 diabetes in people with obesity.”
Reference: Garvey TW, Holst-Hansen T, Laursen PN, Rinnov AR, Wilkinson LH.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.